[
  {
    "ts": "2026-02-18T04:35:48+00:00",
    "headline": "3 Stocks Under $50 with Warning Signs",
    "summary": "Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.",
    "url": "https://finance.yahoo.com/news/3-stocks-under-50-warning-043548048.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "788325ec-3f62-3ee0-a1ba-6dc98164fff8",
      "content": {
        "id": "788325ec-3f62-3ee0-a1ba-6dc98164fff8",
        "contentType": "STORY",
        "title": "3 Stocks Under $50 with Warning Signs",
        "description": "",
        "summary": "Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.",
        "pubDate": "2026-02-18T04:35:48Z",
        "displayTime": "2026-02-18T04:35:48Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/b8535079b0bdf0db49b2ce79ca142b6e",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "MTCH Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ml8G2.BviNhWKnZxJNcE.A--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/b8535079b0bdf0db49b2ce79ca142b6e.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lsrUZ_KQROhzNsMHZUahog--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/b8535079b0bdf0db49b2ce79ca142b6e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-stocks-under-50-warning-043548048.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-stocks-under-50-warning-043548048.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTCH"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "GTES"
            },
            {
              "symbol": "ARHVF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T12:00:00+00:00",
    "headline": "Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission",
    "summary": "Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010 will proceed to review Moderna has received a Prescription Drug User Fee Act (PDUFA) goal ...",
    "url": "https://finance.yahoo.com/news/moderna-announces-u-food-drug-120000188.html",
    "source": "ACCESS Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "d6970553-3341-3d24-a392-a7eaec9e5e52",
      "content": {
        "id": "d6970553-3341-3d24-a392-a7eaec9e5e52",
        "contentType": "STORY",
        "title": "Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission",
        "description": "",
        "summary": "Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010 will proceed to review Moderna has received a Prescription Drug User Fee Act (PDUFA) goal ...",
        "pubDate": "2026-02-18T12:00:00Z",
        "displayTime": "2026-02-18T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "<![CDATA[Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics ...]]>",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y14NrymWnVHtLPxT5mPm5g--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dSewxxG3XkMHQTa3gmVr6w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "ACCESS Newswire",
          "url": "https://www.accessnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-announces-u-food-drug-120000188.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-announces-u-food-drug-120000188.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T14:43:06+00:00",
    "headline": "Berkshire reduces Apple stake, FDA to review Moderna vaccine",
    "summary": "Morning Brief host Julie Hyman takes a look at some of Wednesday morning's trending tickers and stories. Moderna (MRNA) stock is surging on the US Food and Drug Administration's (FDA's) decision to review the company's flu vaccine, reversing its earlier rejection. New York Times (NYT) stock is on the rise after Berkshire Hathaway (BRK-B, BRK-A) announced a $350 million stake in the news outlet. Berkshire also reduced its stake in Apple (AAPL). Palo Alto Networks (PANW) stock is falling after the company lowered its annual profit forecast. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Morning Brief.",
    "url": "https://finance.yahoo.com/video/berkshire-reduces-apple-stake-fda-144306745.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "1e7770c9-6111-3932-bc69-58f45fe0edca",
      "content": {
        "id": "1e7770c9-6111-3932-bc69-58f45fe0edca",
        "contentType": "VIDEO",
        "title": "Berkshire reduces Apple stake, FDA to review Moderna vaccine",
        "description": "<p>Morning Brief host <a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/author/julie-hyman/\">Julie Hyman</a> takes a look at some of Wednesday morning's <a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/markets/stocks/trending/\">trending tickers</a> and stories.</p>\n<p>Moderna (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/MRNA\">MRNA</a>) stock is surging on the US Food and Drug Administration's (FDA's) decision to review the company's flu vaccine, reversing its earlier rejection.</p>\n<p>New York Times (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/NYT\">NYT</a>) stock is on the rise after Berkshire Hathaway (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/BRK-B\">BRK-B</a>, <a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/BRK-A\">BRK-A</a>) announced a $350 million stake in the news outlet. Berkshire also reduced its stake in Apple (<a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/quote/AAPL\">AAPL</a>).</p>\n<p>Palo Alto Networks (<a data-i13n=\"cpos:8;pos:1\" href=\"https://finance.yahoo.com/quote/PANW\">PANW</a>) stock is falling after the company lowered its annual profit forecast.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:9;pos:1\" href=\"https://finance.yahoo.com/videos/series/morning-brief/\">Morning Brief</a>.</p>",
        "summary": "Morning Brief host Julie Hyman takes a look at some of Wednesday morning's trending tickers and stories. Moderna (MRNA) stock is surging on the US Food and Drug Administration's (FDA's) decision to review the company's flu vaccine, reversing its earlier rejection. New York Times (NYT) stock is on the rise after Berkshire Hathaway (BRK-B, BRK-A) announced a $350 million stake in the news outlet. Berkshire also reduced its stake in Apple (AAPL). Palo Alto Networks (PANW) stock is falling after the company lowered its annual profit forecast. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Morning Brief.",
        "pubDate": "2026-02-18T14:43:06Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-02/051c0e30-0cd8-11f1-87da-a82b142176fc",
          "originalWidth": 4200,
          "originalHeight": 2365,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F5HpM6NuKLE4Y9VSSY7A2g--~B/aD0yMzY1O3c9NDIwMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-02/051c0e30-0cd8-11f1-87da-a82b142176fc.cf.webp",
              "width": 4200,
              "height": 2365,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FlZu5KOrihRmvU3Hl65AhA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-02/051c0e30-0cd8-11f1-87da-a82b142176fc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/berkshire-reduces-apple-stake-fda-144306745.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/berkshire-reduces-apple-stake-fda-144306745.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BRK.A"
            },
            {
              "symbol": "BRK-B"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "PANW"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "NYT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T14:47:34+00:00",
    "headline": "US FDA reverses course, will review Moderna's revised flu vaccine application",
    "summary": "Feb 18 (Reuters) - Moderna said on Wednesday the U.S. drug regulator will review its modified flu vaccine application, a week after rejecting the original submission and fueling industry concerns over",
    "url": "https://finance.yahoo.com/news/us-fda-reverses-course-review-124128019.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "a6ff2c57-2099-35b3-85ff-e09366579ac7",
      "content": {
        "id": "a6ff2c57-2099-35b3-85ff-e09366579ac7",
        "contentType": "STORY",
        "title": "US FDA reverses course, will review Moderna's revised flu vaccine application",
        "description": "",
        "summary": "Feb 18 (Reuters) - Moderna said on Wednesday the U.S. drug regulator will review its modified flu vaccine application, a week after rejecting the original submission and fueling industry concerns over",
        "pubDate": "2026-02-18T14:47:34Z",
        "displayTime": "2026-02-18T14:47:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-02/f9aa4b60-08eb-11f1-ab65-4be5d2458423",
          "originalWidth": 4908,
          "originalHeight": 3272,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sTfoGTUUBs4fLFtroDkZVA--~B/aD0zMjcyO3c9NDkwODthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-02/f9aa4b60-08eb-11f1-ab65-4be5d2458423.cf.webp",
              "width": 4908,
              "height": 3272,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zjTL9x_t6HsinV37ZksewA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-02/f9aa4b60-08eb-11f1-ab65-4be5d2458423.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/us-fda-reverses-course-review-124128019.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/us-fda-reverses-course-review-124128019.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T14:12:00+00:00",
    "headline": "FDA Reverses Course and Will Now Review Moderna’s Flu Shot",
    "summary": "The Food and Drug Administration reversed course and agreed to begin a review of  Moderna’s  application to sell a new seasonal flu shot after the vaccine maker agreed to conduct additional testing in the elderly.  The move means that Moderna’s experimental flu shot is largely back on track after the FDA’s surprise decision earlier this month to refuse to start a review of its application.  Moderna said it also met with the FDA and proposed a revised approach.",
    "url": "https://www.wsj.com/health/healthcare/fda-reverses-course-and-will-now-review-modernas-flu-shot-46b3aab1?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "2273a97b-492d-3858-be18-c421379c9e76",
      "content": {
        "id": "2273a97b-492d-3858-be18-c421379c9e76",
        "contentType": "STORY",
        "title": "FDA Reverses Course and Will Now Review Moderna’s Flu Shot",
        "description": "",
        "summary": "The Food and Drug Administration reversed course and agreed to begin a review of  Moderna’s  application to sell a new seasonal flu shot after the vaccine maker agreed to conduct additional testing in the elderly.  The move means that Moderna’s experimental flu shot is largely back on track after the FDA’s surprise decision earlier this month to refuse to start a review of its application.  Moderna said it also met with the FDA and proposed a revised approach.",
        "pubDate": "2026-02-18T14:12:00Z",
        "displayTime": "2026-02-18T14:12:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/2273a97b-492d-3858-be18-c421379c9e76/fda-reverses-course-and-will.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/74f424a7f623387dda6cb598e5c24b4c",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/emrQ_WrCBfJ.TMRxvqPjTQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/74f424a7f623387dda6cb598e5c24b4c.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Eq_mmvWN1.2kFpuLQ.NXMw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/74f424a7f623387dda6cb598e5c24b4c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/healthcare/fda-reverses-course-and-will-now-review-modernas-flu-shot-46b3aab1?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T14:02:41+00:00",
    "headline": "Moderna Jumps After FDA Reverses Decision On Flu Vaccine",
    "summary": "Moderna stock jumped after the Food and Drug Administration reversed its decision not to review the drugmaker's flu vaccine.",
    "url": "https://www.investors.com/news/technology/moderna-stock-mrna-fda-flu-vaccine-reversal/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "99a57f2a-058c-3ce8-ac3e-7178c00a70a5",
      "content": {
        "id": "99a57f2a-058c-3ce8-ac3e-7178c00a70a5",
        "contentType": "STORY",
        "title": "Moderna Jumps After FDA Reverses Decision On Flu Vaccine",
        "description": "",
        "summary": "Moderna stock jumped after the Food and Drug Administration reversed its decision not to review the drugmaker's flu vaccine.",
        "pubDate": "2026-02-18T14:02:41Z",
        "displayTime": "2026-02-18T14:02:41Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/99a57f2a-058c-3ce8-ac3e-7178c00a70a5/moderna-jumps-after-fda.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/63bf0f266eb923d77dbe2608216fb4bd",
          "originalWidth": 945,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w92h_RmcgNt6dFvdhSjzAw--~B/aD01MzM7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/63bf0f266eb923d77dbe2608216fb4bd.cf.webp",
              "width": 945,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wJyadL4qFAB0Nkjx7Gfocg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/63bf0f266eb923d77dbe2608216fb4bd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/moderna-stock-mrna-fda-flu-vaccine-reversal/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T15:22:00+00:00",
    "headline": "Monkeypox Market Competitive Landscape 2026: Comprehensive Insights About 8+ Companies and 10+ Drugs",
    "summary": "Emerging opportunities in the monkeypox treatment and prevention market include innovative vaccine developments by companies such as Bavarian Nordic, BioNTech, and Moderna. The focus is on mRNA-based vaccines and modified vaccines, with numerous clinical trials and strategic collaborations underway to enhance public health responses globally.Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The \"Monkeypox - Competitive Landscape, 2026\" has been added to ResearchAndMarkets.com's offering. The \"Monkeypox",
    "url": "https://finance.yahoo.com/news/monkeypox-market-competitive-landscape-2026-152200128.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "b6df36c9-db3c-3c47-a899-94959b0b5052",
      "content": {
        "id": "b6df36c9-db3c-3c47-a899-94959b0b5052",
        "contentType": "STORY",
        "title": "Monkeypox Market Competitive Landscape 2026: Comprehensive Insights About 8+ Companies and 10+ Drugs",
        "description": "",
        "summary": "Emerging opportunities in the monkeypox treatment and prevention market include innovative vaccine developments by companies such as Bavarian Nordic, BioNTech, and Moderna. The focus is on mRNA-based vaccines and modified vaccines, with numerous clinical trials and strategic collaborations underway to enhance public health responses globally.Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The \"Monkeypox - Competitive Landscape, 2026\" has been added to ResearchAndMarkets.com's offering. The \"Monkeypox",
        "pubDate": "2026-02-18T15:22:00Z",
        "displayTime": "2026-02-18T15:22:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/monkeypox-market-competitive-landscape-2026-152200128.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/monkeypox-market-competitive-landscape-2026-152200128.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BVNKF"
            },
            {
              "symbol": "BNTX"
            },
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T14:45:00+00:00",
    "headline": "Moderna Says FDA Will Review Flu Vaccine, Reversing Earlier Decision. The Stock Is Rising.",
    "summary": "The U.S. Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month.",
    "url": "https://www.barrons.com/articles/moderna-stock-flu-vaccine-fda-f2b4dba6?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "8e03b729-cfc3-3b3c-9cb2-a27e293b0fd8",
      "content": {
        "id": "8e03b729-cfc3-3b3c-9cb2-a27e293b0fd8",
        "contentType": "STORY",
        "title": "Moderna Says FDA Will Review Flu Vaccine, Reversing Earlier Decision. The Stock Is Rising.",
        "description": "",
        "summary": "The U.S. Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month.",
        "pubDate": "2026-02-18T14:45:00Z",
        "displayTime": "2026-02-18T14:45:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8e03b729-cfc3-3b3c-9cb2-a27e293b0fd8/moderna-says-fda-will-review.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/d153a98b1cbf7ba8e382e1ccc0bf075b",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2ls7__o8VHAlLIflOTbbfw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/d153a98b1cbf7ba8e382e1ccc0bf075b.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u965ESXuXpVsZvJ14QP_Bw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/d153a98b1cbf7ba8e382e1ccc0bf075b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/moderna-stock-flu-vaccine-fda-f2b4dba6?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T16:20:43+00:00",
    "headline": "Moderna stock surges as FDA reverses course, agrees to review new flu shot",
    "summary": "Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week.",
    "url": "https://finance.yahoo.com/news/moderna-stock-surges-as-fda-reverses-course-agrees-to-review-new-flu-shot-162043049.html",
    "source": "Yahoo Finance",
    "provider": "yfinance",
    "raw": {
      "id": "4cfb8bc3-ca49-4baf-a920-85e6cc67bbe6",
      "content": {
        "id": "4cfb8bc3-ca49-4baf-a920-85e6cc67bbe6",
        "contentType": "STORY",
        "title": "Moderna stock surges as FDA reverses course, agrees to review new flu shot",
        "description": "",
        "summary": "Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week.",
        "pubDate": "2026-02-18T16:20:43Z",
        "displayTime": "2026-02-18T16:20:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-02/3002f2b0-0ccb-11f1-bdfb-e432c78a6bb6",
          "originalWidth": 4664,
          "originalHeight": 2624,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WmZ3_wvN4V2p.UvvH..bWA--~B/aD0yNjI0O3c9NDY2NDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-02/3002f2b0-0ccb-11f1-bdfb-e432c78a6bb6.cf.webp",
              "width": 4664,
              "height": 2624,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/x4r4v1r90jztIkaJCsEL_Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-02/3002f2b0-0ccb-11f1-bdfb-e432c78a6bb6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance",
          "url": "http://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-stock-surges-as-fda-reverses-course-agrees-to-review-new-flu-shot-162043049.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-stock-surges-as-fda-reverses-course-agrees-to-review-new-flu-shot-162043049.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BNTX"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T16:18:00+00:00",
    "headline": "Moderna’s investigational flu vaccine moves forward in FDA review",
    "summary": "Moderna Inc (NASDAQ:MRNA, XETRA:0QF) announced that the US Food and Drug Administration (FDA) will initiate review of its investigational seasonal influenza vaccine, mRNA-1010, following a Type A meeting between the company and the agency. Shares of Moderna added 6.5% at about $47 on the...",
    "url": "https://www.proactiveinvestors.com/companies/news/1087568/moderna-s-investigational-flu-vaccine-moves-forward-in-fda-review-1087568.html",
    "source": "Proactive",
    "provider": "yfinance",
    "raw": {
      "id": "704473d9-37c3-3d5d-bbc1-81d194c8d25b",
      "content": {
        "id": "704473d9-37c3-3d5d-bbc1-81d194c8d25b",
        "contentType": "STORY",
        "title": "Moderna’s investigational flu vaccine moves forward in FDA review",
        "description": "",
        "summary": "Moderna Inc (NASDAQ:MRNA, XETRA:0QF) announced that the US Food and Drug Administration (FDA) will initiate review of its investigational seasonal influenza vaccine, mRNA-1010, following a Type A meeting between the company and the agency. Shares of Moderna added 6.5% at about $47 on the...",
        "pubDate": "2026-02-18T16:18:00Z",
        "displayTime": "2026-02-18T16:18:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/proactive_us_504/bddabf330125721692b1dc72c403ad56",
          "originalWidth": 1280,
          "originalHeight": 591,
          "caption": "Moderna’s investigational flu vaccine moves forward in FDA review",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MkaNlPJEvcZ9asNiDuD7pg--~B/aD01OTE7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/proactive_us_504/bddabf330125721692b1dc72c403ad56.cf.webp",
              "width": 1280,
              "height": 591,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zg_giT2pqnC38fjYQyzFqg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/proactive_us_504/bddabf330125721692b1dc72c403ad56.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Proactive",
          "url": "https://www.proactiveinvestors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.proactiveinvestors.com/companies/news/1087568/moderna-s-investigational-flu-vaccine-moves-forward-in-fda-review-1087568.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-investigational-flu-vaccine-moves-161800814.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T16:15:07+00:00",
    "headline": "Stocks to Watch Wednesday: Sandisk, Moderna, Caesars, Kenvue",
    "summary": "↗️ Moderna (MRNA): The FDA agreed to review Moderna's seasonal flu shot after the vaccine maker said it would run extra tests in the elderly. Shares jumped 6% following the U-turn. ↗️ Analog Devices (ADI): The chip maker posted better-than-forecast quarterly results and guidance.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-18-2026/card/stocks-to-watch-wednesday-palo-alto-networks-analog-devices-kenvue-Y2BMGWduuDgEfPyyQAcs?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "8c9a9d66-f320-3c4a-bebf-b64d7475d786",
      "content": {
        "id": "8c9a9d66-f320-3c4a-bebf-b64d7475d786",
        "contentType": "STORY",
        "title": "Stocks to Watch Wednesday: Sandisk, Moderna, Caesars, Kenvue",
        "description": "",
        "summary": "↗️ Moderna (MRNA): The FDA agreed to review Moderna's seasonal flu shot after the vaccine maker said it would run extra tests in the elderly. Shares jumped 6% following the U-turn. ↗️ Analog Devices (ADI): The chip maker posted better-than-forecast quarterly results and guidance.",
        "pubDate": "2026-02-18T16:15:07Z",
        "displayTime": "2026-02-18T16:15:07Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8c9a9d66-f320-3c4a-bebf-b64d7475d786/stocks-to-watch-wednesday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/c9a8e42f78f26dfe0cee83cd1f9e6456",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bbpKzuStgVf0Et0UovLfBA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/c9a8e42f78f26dfe0cee83cd1f9e6456.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Qz4bi0UMnDa90cPa6Lw6lA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/c9a8e42f78f26dfe0cee83cd1f9e6456.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-18-2026/card/stocks-to-watch-wednesday-palo-alto-networks-analog-devices-kenvue-Y2BMGWduuDgEfPyyQAcs?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "BLSFY"
            },
            {
              "symbol": "SNDK"
            },
            {
              "symbol": "CZR"
            },
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "ADI"
            },
            {
              "symbol": "WDC"
            },
            {
              "symbol": "STLD"
            },
            {
              "symbol": "KMB"
            },
            {
              "symbol": "BLSFF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T16:10:18+00:00",
    "headline": "Moderna Loses Two Defenses in Patent Infringement Case Against Arbutus Biopharma",
    "summary": "Moderna (MRNA) faced a setback in a patent infringement case after a Delaware federal court dismisse",
    "url": "https://finance.yahoo.com/news/moderna-loses-two-defenses-patent-161018329.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "be19613b-6703-3dc4-9ded-64ca0ac263e1",
      "content": {
        "id": "be19613b-6703-3dc4-9ded-64ca0ac263e1",
        "contentType": "STORY",
        "title": "Moderna Loses Two Defenses in Patent Infringement Case Against Arbutus Biopharma",
        "description": "",
        "summary": "Moderna (MRNA) faced a setback in a patent infringement case after a Delaware federal court dismisse",
        "pubDate": "2026-02-18T16:10:18Z",
        "displayTime": "2026-02-18T16:10:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-loses-two-defenses-patent-161018329.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-loses-two-defenses-patent-161018329.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "ABUS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T16:03:00+00:00",
    "headline": "Cancer Vaccines Competitive Landscape Report 2026: Comprehensive Insights About 250+ Companies and 300+ Drugs - Collaborations and Licensing by Key Players Like Moderna, Merck, and IO Biotech",
    "summary": "The cancer vaccine market presents opportunities in personalized and therapeutic vaccines, innovations in delivery strategies, and combination therapies. Collaborations and licensing by key players like Moderna, Merck, and IO Biotech drive industry progression. Challenges remain in broadening efficacy and optimizing delivery platforms.Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The \"Cancer Vaccines - Competitive Landscape, 2026\" has been added to ResearchAndMarkets.com's offering. This report offe",
    "url": "https://finance.yahoo.com/news/cancer-vaccines-competitive-landscape-report-160300672.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "3f4a0bc7-63c6-3efa-8e10-343560fcf25b",
      "content": {
        "id": "3f4a0bc7-63c6-3efa-8e10-343560fcf25b",
        "contentType": "STORY",
        "title": "Cancer Vaccines Competitive Landscape Report 2026: Comprehensive Insights About 250+ Companies and 300+ Drugs - Collaborations and Licensing by Key Players Like Moderna, Merck, and IO Biotech",
        "description": "",
        "summary": "The cancer vaccine market presents opportunities in personalized and therapeutic vaccines, innovations in delivery strategies, and combination therapies. Collaborations and licensing by key players like Moderna, Merck, and IO Biotech drive industry progression. Challenges remain in broadening efficacy and optimizing delivery platforms.Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The \"Cancer Vaccines - Competitive Landscape, 2026\" has been added to ResearchAndMarkets.com's offering. This report offe",
        "pubDate": "2026-02-18T16:03:00Z",
        "displayTime": "2026-02-18T16:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cancer-vaccines-competitive-landscape-report-160300672.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cancer-vaccines-competitive-landscape-report-160300672.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "IOBT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T09:24:47+00:00",
    "headline": "FDA reverses course on Moderna’s flu vaccine",
    "summary": "Moderna said after a \"Type A\" meeting, the agency agreed to move forward and review its application for the mRNA-based shot.",
    "url": "https://www.biopharmadive.com/news/fda-reverses-course-review-moderna-approval-application-influenza-/812432/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "cd2e2558-4ddf-3094-ab21-c1ade8ae3c6e",
      "content": {
        "id": "cd2e2558-4ddf-3094-ab21-c1ade8ae3c6e",
        "contentType": "STORY",
        "title": "FDA reverses course on Moderna’s flu vaccine",
        "description": "",
        "summary": "Moderna said after a \"Type A\" meeting, the agency agreed to move forward and review its application for the mRNA-based shot.",
        "pubDate": "2026-02-18T09:24:47Z",
        "displayTime": "2026-02-18T09:24:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/6f1aeaf3c7b754444446c9ea87957a57",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lkx01CaP1sQh8nzs.uZmqQ--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/6f1aeaf3c7b754444446c9ea87957a57.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G5ki8L6F4.VmKiLOMdWvgg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/6f1aeaf3c7b754444446c9ea87957a57.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/fda-reverses-course-review-moderna-approval-application-influenza-/812432/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-reverses-course-moderna-flu-092447924.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T18:39:47+00:00",
    "headline": "In reversal, US FDA will review Moderna's flu vaccine application",
    "summary": "<body><p>STORY: The U.S. Food and Drug Administration will review Moderna's modified flu vaccine application, a week after the agency rejected the company's original submission.</p><p>That's according to the drugmaker, whose shares rose as much as 8.5% Wednesday morning on the news.</p><p>The FDA's initial refusal to review Moderna's vaccine application had amplified concerns about a sharp shift in U.S. vaccine policy under the Trump administration.</p><p>That policy, spearheaded by U.S. Health Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic, has contributed to falling vaccination rates and reshaped the regulatory landscape for new shots.</p><p>In its initial rejection, the FDA said Moderna should have given a higher-strength vaccine to older patients in the control arm of its trial.</p><p>Moderna said the FDA has now accepted its revised application seeking full approval for the shot for adults aged 50 to 64, and accelerated approval for those aged 65 and above.</p><p>One analyst told Reuters the agency's about-face potentially brings back a revenue stream for Moderna that \"had been in limbo.\"</p><p>The HHS, which oversees the FDA, was not immediately available for comment.</p><p>The FDA is expected to make a decision on the vaccine by August 5.</p></body>",
    "url": "https://finance.yahoo.com/video/reversal-us-fda-review-modernas-183947758.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "c8c771a7-5b5b-3218-a827-1d42af859945",
      "content": {
        "id": "c8c771a7-5b5b-3218-a827-1d42af859945",
        "contentType": "VIDEO",
        "title": "In reversal, US FDA will review Moderna's flu vaccine application",
        "description": "<title><body><p>STORY: The U.S. Food and Drug Administration will review Moderna's modified flu vaccine application, a week after the agency rejected the company's original submission.</p><p>That's according to the drugmaker, whose shares rose as much as 8.5% Wednesday morning on the news.</p><p>The FDA's initial refusal to review Moderna's vaccine application had amplified concerns about a sharp shift in U.S. vaccine policy under the Trump administration.</p><p>That policy, spearheaded by U.S. Health Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic, has contributed to falling vaccination rates and reshaped the regulatory landscape for new shots.</p><p>In its initial rejection, the FDA said Moderna should have given a higher-strength vaccine to older patients in the control arm of its trial.</p><p>Moderna said the FDA has now accepted its revised application seeking full approval for the shot for adults aged 50 to 64, and accelerated approval for those aged 65 and above.</p><p>One analyst told Reuters the agency's about-face potentially brings back a revenue stream for Moderna that \"had been in limbo.\"</p><p>The HHS, which oversees the FDA, was not immediately available for comment.</p><p>The FDA is expected to make a decision on the vaccine by August 5.</p></body></title>",
        "summary": "<body><p>STORY: The U.S. Food and Drug Administration will review Moderna's modified flu vaccine application, a week after the agency rejected the company's original submission.</p><p>That's according to the drugmaker, whose shares rose as much as 8.5% Wednesday morning on the news.</p><p>The FDA's initial refusal to review Moderna's vaccine application had amplified concerns about a sharp shift in U.S. vaccine policy under the Trump administration.</p><p>That policy, spearheaded by U.S. Health Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic, has contributed to falling vaccination rates and reshaped the regulatory landscape for new shots.</p><p>In its initial rejection, the FDA said Moderna should have given a higher-strength vaccine to older patients in the control arm of its trial.</p><p>Moderna said the FDA has now accepted its revised application seeking full approval for the shot for adults aged 50 to 64, and accelerated approval for those aged 65 and above.</p><p>One analyst told Reuters the agency's about-face potentially brings back a revenue stream for Moderna that \"had been in limbo.\"</p><p>The HHS, which oversees the FDA, was not immediately available for comment.</p><p>The FDA is expected to make a decision on the vaccine by August 5.</p></body>",
        "pubDate": "2026-02-18T18:39:47Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/uxBCwggo6QTXxe02Ol0lAg--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/4123de00-a723-4c04-b9a8-ac59c2a34bf3/main/1280x720/43s584ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AQX1V0HBZ5O2y6p4ONmHKA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/4123de00-a723-4c04-b9a8-ac59c2a34bf3/main/1280x720/43s584ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gPLbqu1zZucBVMp.9M5t8w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/4123de00-a723-4c04-b9a8-ac59c2a34bf3/main/1280x720/43s584ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/reversal-us-fda-review-modernas-183947758.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/reversal-us-fda-review-modernas-183947758.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T18:35:32+00:00",
    "headline": "Why Moderna Stock Just Popped",
    "summary": "So the FDA will consider Moderna's flu vaccine application after all. Does this make Moderna stock a buy?",
    "url": "https://www.fool.com/investing/2026/02/18/why-moderna-stock-just-popped/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "9032ceea-7d9c-3170-ac81-78e5291548cc",
      "content": {
        "id": "9032ceea-7d9c-3170-ac81-78e5291548cc",
        "contentType": "STORY",
        "title": "Why Moderna Stock Just Popped",
        "description": "",
        "summary": "So the FDA will consider Moderna's flu vaccine application after all. Does this make Moderna stock a buy?",
        "pubDate": "2026-02-18T18:35:32Z",
        "displayTime": "2026-02-18T18:35:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/44964a1ac9e94b02e68a8d77e3a343b0",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "Chinese doctor in clean suit examining a capped bottle of vaccine.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nd3ma7X1eCCvkJpSzV1txw--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/44964a1ac9e94b02e68a8d77e3a343b0.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SfQ2hx4wkCt4gkDY0fN90Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/44964a1ac9e94b02e68a8d77e3a343b0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/18/why-moderna-stock-just-popped/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-moderna-stock-just-popped-183532047.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T18:08:08+00:00",
    "headline": "Moderna says FDA to review its flu vaccine after reversing course",
    "summary": "With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.",
    "url": "https://www.cbsnews.com/news/moderna-fda-flu-vaccine-mrna-reverse-decision/?ftag=YHF4eb9d17",
    "source": "CBS News",
    "provider": "yfinance",
    "raw": {
      "id": "9da8e331-f62a-37e3-9858-a4c9d7ad2501",
      "content": {
        "id": "9da8e331-f62a-37e3-9858-a4c9d7ad2501",
        "contentType": "STORY",
        "title": "Moderna says FDA to review its flu vaccine after reversing course",
        "description": "",
        "summary": "With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.",
        "pubDate": "2026-02-18T18:08:08Z",
        "displayTime": "2026-02-18T18:08:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/cbs_news_897/a373a5a991a5ad4e721f3546c1f00e43",
          "originalWidth": 6779,
          "originalHeight": 4519,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tq_anMrpa0BASWlr39sfwg--~B/aD00NTE5O3c9Njc3OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/cbs_news_897/a373a5a991a5ad4e721f3546c1f00e43.cf.webp",
              "width": 6779,
              "height": 4519,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lE_vTS29e00R_B30bViz5A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cbs_news_897/a373a5a991a5ad4e721f3546c1f00e43.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "CBS News",
          "url": "https://www.cbsnews.com/"
        },
        "canonicalUrl": {
          "url": "https://www.cbsnews.com/news/moderna-fda-flu-vaccine-mrna-reverse-decision/?ftag=YHF4eb9d17",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-says-fda-review-flu-170613728.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T18:01:55+00:00",
    "headline": "FDA to review Moderna’s flu jab on agency pivot",
    "summary": "The PDUFA date for mRNA-1010 in seasonal influenza is set for 5 August 2026, meaning the vaccine could be on the market for the 2026/2027 flu season.",
    "url": "https://www.pharmaceutical-technology.com/news/fda-to-review-moderna-seasonal-flu-vaccine-mrna-1010/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "55874e7f-72b4-36b9-8d6e-40342ebdf814",
      "content": {
        "id": "55874e7f-72b4-36b9-8d6e-40342ebdf814",
        "contentType": "STORY",
        "title": "FDA to review Moderna’s flu jab on agency pivot",
        "description": "",
        "summary": "The PDUFA date for mRNA-1010 in seasonal influenza is set for 5 August 2026, meaning the vaccine could be on the market for the 2026/2027 flu season.",
        "pubDate": "2026-02-18T18:01:55Z",
        "displayTime": "2026-02-18T18:01:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/6ae39d0e013c4f717772ececac9bde81",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "If approved",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Hu5Jc8.Thhf42O.tTfRH0A--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/6ae39d0e013c4f717772ececac9bde81.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q1d2gz1.DWVs7N1coTkaCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/6ae39d0e013c4f717772ececac9bde81.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/fda-to-review-moderna-seasonal-flu-vaccine-mrna-1010/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-review-moderna-flu-jab-180155623.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T17:12:00+00:00",
    "headline": "Moderna Stock Rises. FDA Will Review Its Seasonal Flu Vaccine After All.",
    "summary": "The Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month.",
    "url": "https://www.barrons.com/articles/moderna-stock-flu-vaccine-fda-f2b4dba6?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "8e03b729-cfc3-3b3c-9cb2-a27e293b0fd8",
      "content": {
        "id": "8e03b729-cfc3-3b3c-9cb2-a27e293b0fd8",
        "contentType": "STORY",
        "title": "Moderna Stock Rises. FDA Will Review Its Seasonal Flu Vaccine After All.",
        "description": "",
        "summary": "The Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month.",
        "pubDate": "2026-02-18T17:12:00Z",
        "displayTime": "2026-02-18T17:12:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8e03b729-cfc3-3b3c-9cb2-a27e293b0fd8/moderna-stock-rises-fda-will.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/d153a98b1cbf7ba8e382e1ccc0bf075b",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2ls7__o8VHAlLIflOTbbfw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/d153a98b1cbf7ba8e382e1ccc0bf075b.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u965ESXuXpVsZvJ14QP_Bw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/d153a98b1cbf7ba8e382e1ccc0bf075b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/moderna-stock-flu-vaccine-fda-f2b4dba6?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T15:33:00+00:00",
    "headline": "These Stocks Are Today’s Movers: Nvidia, Palantir, Moderna, Global Payments, Garmin, Caesars, Palo Alto, and More",
    "summary": "Facebook owner  Meta Platforms  is expanding its business with the chip designer in a deal likely to be worth tens of billions of dollars.  Meta will use millions of Nvidia’s Blackwell and Rubin graphics processing units, a reminder that Nvidia is still the leading player in artificial-intelligence processors.  Meta shares were flat in premarket trading, having taken a beating in recent weeks due to concerns around the company’s AI spending plans.",
    "url": "https://www.barrons.com/articles/stock-movers-726553ad?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ef026f8c-269f-3106-8b88-ed03e4a6f8ac",
      "content": {
        "id": "ef026f8c-269f-3106-8b88-ed03e4a6f8ac",
        "contentType": "STORY",
        "title": "These Stocks Are Today’s Movers: Nvidia, Palantir, Moderna, Global Payments, Garmin, Caesars, Palo Alto, and More",
        "description": "",
        "summary": "Facebook owner  Meta Platforms  is expanding its business with the chip designer in a deal likely to be worth tens of billions of dollars.  Meta will use millions of Nvidia’s Blackwell and Rubin graphics processing units, a reminder that Nvidia is still the leading player in artificial-intelligence processors.  Meta shares were flat in premarket trading, having taken a beating in recent weeks due to concerns around the company’s AI spending plans.",
        "pubDate": "2026-02-18T15:33:00Z",
        "displayTime": "2026-02-18T15:33:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ef026f8c-269f-3106-8b88-ed03e4a6f8ac/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/75fb8abe0cb3e241653dac6763dc2b1a",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oH4YA.VwuKvek8N41letGg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/75fb8abe0cb3e241653dac6763dc2b1a.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4MYHMGOSVh_Kw1LpvaA55Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/75fb8abe0cb3e241653dac6763dc2b1a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-726553ad?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "SNDK"
            },
            {
              "symbol": "META"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "GPN"
            },
            {
              "symbol": "GRMN"
            },
            {
              "symbol": "PANW"
            },
            {
              "symbol": "ADI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T17:55:00+00:00",
    "headline": "These Stocks Are Today’s Movers: Nvidia, Palantir, Garmin, Global Payments, Palo Alto, Moderna, Caesars, and More",
    "summary": "Facebook owner  Meta Platforms  is expanding its business with the chip designer in a deal likely to be worth tens of billions of dollars.  Meta will use millions of Nvidia’s Blackwell and Rubin graphics processing units, a reminder that Nvidia is still the leading player in artificial-intelligence processors.  Meta shares were flat in premarket trading, having taken a beating in recent weeks due to concerns around the company’s AI spending plans.",
    "url": "https://www.barrons.com/articles/stock-movers-726553ad?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ef026f8c-269f-3106-8b88-ed03e4a6f8ac",
      "content": {
        "id": "ef026f8c-269f-3106-8b88-ed03e4a6f8ac",
        "contentType": "STORY",
        "title": "These Stocks Are Today’s Movers: Nvidia, Palantir, Garmin, Global Payments, Palo Alto, Moderna, Caesars, and More",
        "description": "",
        "summary": "Facebook owner  Meta Platforms  is expanding its business with the chip designer in a deal likely to be worth tens of billions of dollars.  Meta will use millions of Nvidia’s Blackwell and Rubin graphics processing units, a reminder that Nvidia is still the leading player in artificial-intelligence processors.  Meta shares were flat in premarket trading, having taken a beating in recent weeks due to concerns around the company’s AI spending plans.",
        "pubDate": "2026-02-18T17:55:00Z",
        "displayTime": "2026-02-18T17:55:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ef026f8c-269f-3106-8b88-ed03e4a6f8ac/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/75fb8abe0cb3e241653dac6763dc2b1a",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oH4YA.VwuKvek8N41letGg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/75fb8abe0cb3e241653dac6763dc2b1a.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4MYHMGOSVh_Kw1LpvaA55Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/75fb8abe0cb3e241653dac6763dc2b1a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-726553ad?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "META"
            },
            {
              "symbol": "SNDK"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "GRMN"
            },
            {
              "symbol": "GPN"
            },
            {
              "symbol": "PANW"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "ADI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]